Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose–response meta-analysis
Yu-Wei Lin, Yang-Chieh Brian Chen, Kuo-Chuan Hung, Chih-Sung Liang, Ping-Tao Tseng, Andre F Carvalho, Eduard Vieta, Marco Solmi, Edward Chia-Cheng Lai, Pao-Yen Lin, Chih-Wei Hsu, Yu-Kang Tu · 2024
Read Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose–response meta-analysis by Yu-Wei Lin, Yang-Chieh Brian Chen, Kuo-Chuan Hung, Chih-Sung Liang, Ping-Tao Tseng, Andre F Carvalho, Eduard Vieta, Marco Solmi, Edward Chia-Cheng Lai, Pao-Yen Lin, Chih-Wei Hsu, Yu-Kang Tu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11574478.txt.
Description
Yu-Wei Lin and co-authors pool trials to find the best dose of a drug for bipolar depression in a 2024 review. Five trials with over two thousand patients fed a dose response model. Outcomes covered mood, worry, function, dropout, and body chemistry shifts. Six week courses formed the typical test window.
Forty to sixty milligrams daily gave the best balance in the model. Mood gains peaked near fifty milligrams across several scales. Side effects rose with dose, while dropout and mood switch risks stayed flat. Weight crept up at low doses and blood sugar at high ones. A hormone marker rose in both sexes with dose. The authors name the mid range as the reasonable choice.
Catalog record
| CREATOR | Yu-Wei Lin, Yang-Chieh Brian Chen, Kuo-Chuan Hung, Chih-Sung Liang, Ping-Tao Tseng, Andre F Carvalho, Eduard Vieta, Marco Solmi, Edward Chia-Cheng Lai, Pao-Yen Lin, Chih-Wei Hsu, Yu-Kang Tu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |